Andre De Jesus Ferreira dos Santos @LongTheWorld: "A deep dive into $VEEV..."

Switzerland

A deep dive into $VEEV (Veeva Systems Inc A) — a leading cloud software provider focused on the life sciences industry (pharma, biotech, medtech, etc.). At the current price of ~$175 and a market cap of ~$29B, I believe $VEEV will create great shareholder value in the years ahead. 𝘾𝙖𝙨𝙝 𝙈𝙖𝙘𝙝𝙞𝙣𝙚 & 𝙂𝙧𝙤𝙬𝙩𝙝: Veeva delivered consistent, high-quality revenue growth of +16% YoY in FY2026, driven by its sticky subscription-heavy B2B SaaS model (subscription revenue made up ~84% of the total and grew 17% YoY). It's a high-margin, low-capital-intensity business with excellent operating leverage. FY2026 Revenue: $3.195 billion (+16% YoY) Free Cash Flow: ~$1.39 billion (~43.5% FCF margin) 𝘽𝙖𝙡𝙖𝙣𝙘𝙚 𝙎𝙝𝙚𝙚𝙩: Cash & short-term investments sit at $6.56 billion! That’s ~22.6% of its market cap, bringing the enterprise value down to roughly $22.4B. With zero debt, bankruptcy risk is nearly impossible… although I know some people who enjoy challenges and would still try. 𝘼𝙘𝙦𝙪𝙞𝙨𝙞𝙩𝙞𝙤𝙣𝙨 𝙎𝙪𝙢𝙢𝙖𝙧𝙮: Despite its massive cash pile, Veeva follows a disciplined tuck-in acquisition strategy focused on filling strategic gaps in its Vault ecosystem — without overpaying or diluting shareholders. It has a clear bias toward small, high-fit deals. Recent moves include: * Ostro (March 2026, ~$100M): Leading AI-driven brand engagement platform for life sciences. Enables compliant, conversational AI for patients and doctors on brand websites. Ostro operates as an independent unit but will integrate with Veeva Commercial Cloud to connect online and field engagement. * Veracity Logic (2021/2022, undisclosed): Strengthened Vault RTSM (randomization and trial supply management) for clinical trials. * Crossix (2019, $430M cash + ~$120M equity grants for employees): Added privacy-safe data capabilities that power Veeva’s analytics and real-world evidence offerings. 𝙎𝙖𝙡𝙚𝙨𝙛𝙤𝙧𝙘𝙚 𝙖𝙨 𝘾𝙤𝙢𝙥𝙚𝙩𝙞𝙩𝙞𝙤𝙣: Veeva used to pay $CRM (Salesforce Inc) a licensing fee for every user, and in exchange, Salesforce agreed not to compete in the life sciences space. In late 2022, Veeva announced it would not renew this agreement. The contract officially expired in September 2025, so Salesforce can now compete directly for Veeva’s customers. However, Veeva was well prepared, CRM was its first product, but thanks to the strong growth and diversification into the broader Vault platform, it now represents only ~20% of revenue and is expected to contribute around 10% by 2030. The elimination of the Salesforce fee will either allow Veeva to lower prices or expand margins. Veeva remains the clear market leader in regulated life-sciences CRM. 𝙍𝙚𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝙖𝙨 𝙖 𝙈𝙤𝙖𝙩: Life sciences operates under some of the strictest global regulations in any industry. Veeva’s strength is a powerful combination of deep regulatory compliance expertise + high switching costs + industry-specific integration + earned customer trust. This makes it a far superior solution versus generalist platforms like $CRM and $ORCL (Oracle Corporation) . There are other niche players like $IQV (IQVIA Holdings Inc.), which focus more on data, analytics, and services. Yet most large pharma companies still use both $IQV and $VEEV — because they prefer Veeva’s CRM and Vault tools as the compliant “system of record.” These two companies, which once battled legally over software integration and data sharing, now have an official global partnership announced in August 2025. It fully embraces the “use both” reality, making integration smooth and customers happy. 𝙁𝙤𝙪𝙣𝙙𝙚𝙧 & 𝙈𝙖𝙟𝙤𝙧 𝙊𝙬𝙣𝙚𝙧: Peter Gassner, Veeva’s founder and longtime CEO (since 2007), remains deeply aligned with shareholders. He owns approximately 7.5% of the company (~12.27 million shares), worth over $2 billion at current prices. This makes him the largest individual shareholder and ties his personal wealth directly to Veeva’s long-term success. Gassner’s vision — building industry-specific, highly compliant vertical SaaS — has driven Veeva’s dominance. His continued leadership and significant skin in the game give strong confidence in disciplined execution, capital allocation, and strategic focus. 𝙎&𝙋 𝟱𝟬𝟬 𝙄𝙣𝙘𝙡𝙪𝙨𝙞𝙤𝙣 𝘾𝙖𝙩𝙖𝙡𝙮𝙨𝙩: The S&P 500 has strict eligibility rules, but Veeva currently passes all of them. The stock is highly liquid, has a high public float, and its market cap is larger than ~30% of the companies already in the index. It has been GAAP profitable for over a decade and trades on the NYSE. Any inclusion announcement would trigger massive buy flow from indexed funds plus broader recognition and re-rating. 𝙈𝙮 𝙫𝙞𝙚𝙬: $VEEV offers a high-quality compounder with a fortress balance sheet, wide regulatory moat, founder alignment, disciplined M&A, and multiple catalysts, including its first-ever $2 billion buyback program. This company is well positioned to create significant long-term value for shareholders and all its stakeholders. The post has too many chars already, sources linked in a comment below…

Not investment advice. The author may have financial interests in the mentioned instruments.